Tang Capital Management Reports About 10% Of Inovio — Warrants Limit Its Reported Holding

The affiliated holders certified a passive position, with most warrant shares excluded by an exercise cap.

Share
Tang Capital Management Reports About 10% Of Inovio — Warrants Limit Its Reported Holding

Tang Capital Management reported a roughly 10% stake in Inovio Pharmaceuticals, which develops DNA medicines for HPV-linked diseases, cancer and infectious diseases. Its passive ownership disclosure filed Monday put the position at 17,978,200 beneficially owned shares as of November 6, with warrant exercise caps limiting the shares counted.

The warrant cap sets the count

The reported position represents 9.99% of Inovio's common-stock class. It includes 17,659,259 common shares and 318,941 shares obtainable by exercising pre-funded warrants — instruments that can be exchanged for common shares.

Tang Capital Management holds 10,150,264 pre-funded warrants, each convertible into one common share. The warrants bar exercises that would take ownership above 9.99%, counting affiliates and others acting as a group.

The holders can increase the limit to no more than 19.99%, to the extent required by applicable Nasdaq rules. That requires written notice to Inovio, and the higher threshold takes effect only after a 61-day wait.

The ownership calculation uses a denominator of 179,961,968 shares. That combines Inovio's 179,643,027 outstanding common shares as of November 6 with the 318,941 warrant shares currently available for exercise.

Shared authority across Tang entities

Tang Capital Management is the general partner of Tang Capital Partners and Tang Capital Partners International. Kevin Tang, its manager and the chief executive of Tang Capital Partners III and Tang Capital Partners IV, shares voting and sale authority over the reported position with the firm and affiliated holders.

Tang Capital Partners III and Tang Capital Partners IV are indirectly wholly owned by Tang Capital Partners. The reporting persons certified that their securities were acquired and held without a purpose of changing or influencing Inovio's control.

DNA medicines still in development

Inovio's lead candidate, INO-3107, targets recurrent respiratory papillomatosis, a rare condition that produces airway tumors. Other candidates target throat cancer and other cancers.

The medicines use small circular DNA molecules to instruct cells to produce specific proteins. Inovio's CELLECTRA devices help deliver them into cells using short electrical pulses.

All candidates remain in research and development. Inovio has earned no revenue from product sales; its revenue comes from licensing fees, milestone payments and collaborative research agreements and contracts.

The company's annual-report profile says its DNA medicines have been administered over 19,000 times to nearly 6,000 participants.

The reported ownership therefore includes only 318,941 exercisable warrant shares, alongside the 17,659,259 common shares already held.

Sources

More on Inovio Pharmaceuticals

All Inovio Pharmaceuticals (INO) coverage →